Kornimate/medical-research-clean huggingface dataset:
chloroquine in combination with carboplatin/gemcitabine in advanced solid tumors

Conditions: Malignant Neoplasm; Solid Tumors

Summary: the purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors. also, the research study will be increasing the dose of chloroquine to find the highest dose of chloroquine that can be given in combination with carboplatin and gemcitabine without causing severe side effects.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a malignancy that is metastatic or unresectable and for which either standard curative measures do not exist or are no longer effective and carboplatin/gemcitabine is considered a reasonable treatment option whether first line or acceptable and approved combination therapy. * age \>18 years of age. * performance status less than or equal 2 (karnofsky \>60%) * life expectancy of greater than 3 months. * adequate labs * measurable disease exclusion criteria: * current treatment with any other investigational agents. * patients with untreated brain metastases * history of allergic reaction attributed to compounds of similar chemical or biologic composition to chloroquine or other agents used in study.
observational study with pascallerg ® in patients with hay fever

Conditions: Hay Fever

Summary: the aim of this observational study is to document the therapeutic use of pascallerg ® for hay fever. based on the survey is a decrease in disease-specific symptoms when taking pascallerg ® over a period of 4 weeks will be documented. in addition to the compatibility can be assessed.

there are documented male and female patients over the age of one year who suffer from hay fever. the traetment time is about a period of 4 weeks with pascallerg® tablets.

Eligibility criteria:
inclusion criteria: * hay fever exclusion criteria: * lactose intolerance and / or * chromium hypersensitivity

Keywords: hay fever pascallerg
chinese second hip fracture evaluation

Conditions: Hip Fractures; Osteoporosis

Summary: 1. to compare overall rates of second hip fractures in both genders, 2. to determine the effect of hip fracture on proximal femoral volumetric bone mineral density (vbmd), bone structure and muscle by quantitative computed tomography(qct), 3. to evaluate the contribution of qct-image analysis to the prediction of the second hip fracture risk. 4. to identify the differences between femoral neck fracture and trochanter fracture following hip fracture

osteoporotic hip fracture is a great harm among elderly people, for whom disability and death often occurs. furthermore, sustaining an osteoporotic hip fracture increases the risk of a subsequent fracture. however, the risk factors of subsequent hip fractures are less studied and the proximal femur bone structure and muscle changes following first hip fracture are little known. therefore, we propose to conduct an observational and perspective study to assess the effect of hip fracture on proximal femoral bone and muscle using quantitative computed tomography (qct), as well as to evaluate the contribution of qct-image analysis to the prediction of the second hip fracture risk. as hip fractures are divided into two major anatomic based types in clinical: femoral neck fractures (intracapsular) and trochanter fractures (extracapsular), the fundamental objective also includes identifying bone and muscle differences in a union activity between the two type fractures. compared with duel-energy x-ray absorptiometry (dxa), qct offers the advantage of selective measurement of the metabolically active and structurally important trabecular bone in the proximal femoral. volumetric bmd and structure of proximal femoral and muscle around hip will be measured with qct. the ct scanner will be the clinical ct scanner of the local participated center. quality control and monitoring will be conducted by beijing jishuitan hospital, as well as the centralised image interpretation.

Eligibility criteria:
inclusion criteria: * a:osteoporotic patients b:osteoporotic hip fracture patients (femoral neck fracture and femoral trochanteric fracture) c: be willing to and be able to join in the study and sighed the informed consent exclusion criteria: * a:under 47years old b:non-surgical repair of hip fracture c:pathologic fracture d:violence-related trauma e:bilateral hip implants or have hip replacement on the non-fractured side

Keywords: second hip fracture quantitative computed tomography bone structure muscle
dynamic myocardial perfusion imaging by 320 multidetector computed tomography

Conditions: Coronary Heart Disease

Summary: recent advances in technology have resulted in the development of scanners that can image the heart blood vessels within 10 to 20 minutes but without the need for admission to hospital or insertion of catheters. further advances in technology allow the visualisation of both the blood vessels and the supply of blood to the heart muscle. here we propose to assess the latest and most powerful computed tomography scanner and compare it to magnetic resonance and conventional coronary angiography.


Eligibility criteria:
inclusion criteria: * referred for invasive coronary angiography because of suspected coronary heart disease exclusion criteria: * inability or unwillingness to undergo computed tomography or magnetic resonance imaging * renal failure (serum creatinine \>200 micromol/l or estimated glomerular filtration rate \<30 ml/min) * hepatic failure * allergy to iodinated contrast or gadolinium * pregnancy * contraindication to adenosine infusion * inability to give informed consent * inability to perform fractional flow reserve during invasive coronary angiography

Keywords: computed tomography myocardial perfusion coronary heart disease
degenerative scoliosis

Conditions: Degenerative Scoliosis

Summary: several deformities of the spine exist such as degenerative lumbar scoliosis. these deformities can generate functional discomfort and limit the patient's quality of life. in the event of severe trunk imbalance and progression of the deformity, operative correction of the spinal deformity by instrumentation and posterior arthrodesis may be indicated. surgical techniques and instrumentation have evolved over the past 5 years. these changes in surgical strategies have a potential impact on the patient's quality of life and the correction results in the medium and long term. the aim of the study is the analysis of surgical corrections obtained and radiological changes over time with classic 2-rod techniques versus modern 4-rod instrumentation techniques


Eligibility criteria:
inclusion criteria: * major subjects\> 18 years old * subject with a surgical indication for arthrodesis and surgical correction of degenerative scoliosis * subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: degenerative scoliosis degenerative lumbar scoliosis scoliosis
evaluation of efficacy/safety of eve-pms skin test panel

Conditions: Premenstrual Syndrome

Summary: the eve-pms technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe premenstrual syndrome (pms). the system includes skin testing panel for identification of hormones to which the patients might be sensitive. tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. results of skin tests and patient's history will determine the value of eve-pms skin-test panel as a diagnostic tool for severe pms patients.


Eligibility criteria:
inclusion criteria: 1. person is over the age of 20 but not older than age 45. 2. person is willing to participate as evidenced by signing the written informed consent form. 3. suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of pms symptoms severity) 4. other severe symptoms of premenstrual syndrome (based on who and acog criteria). this may include one or more of pms symptoms with level 7-10 according to standard scale of pms symptoms severity. 5. at work, school, home, or in daily routine, at least one of the pms symptoms caused reduction of productivity or inefficiency 6. at least one of the pms symptoms caused avoidance of or less participation in hobbies or social activities 7. at least one of the pms symptoms interfere with relationships with others: i. timing of pms symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow. ii. pattern and length of pms symptomatic period: minimum of 2 days, up to 14 days. iii. for pms diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms. iv. timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual cycle. v. cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from no pms symptoms to pms symptoms. vi. reliable non hormonal contraception. exclusion criteria: 1. pregnant or lactating woman 2. oral contraceptives during last three months, including hormonal iud (trade name mirena). 3. serious health problems. 4. unexplained menstrual disorders. 5. treated by hormones (estrogen and progesterone). 6. for healthy: irregular or abnormal test results.

Keywords: pms hormones skin tests allergen immunotherapy
effectiveness and durability long-term results of tricuspid annuloplasty with 3d shaped rings.

Conditions: Functional Tricuspid Regurgitation

Summary: interest in tricuspid valve disease has grown exponentially over the past few years, in response to increased interest in the poor prognosis of patients with functional tricuspid regurgitation (tr). tricuspid valve repair (tvr) using a prosthetic ring represents the first option in many centers worldwide, due to the low incidence of residual and recurrent tr and improved survival compared to suture techniques. the goal of ring annuloplasty is to restore the normal geometry of the annulus, thereby improving the coaptation of the leaflets and preventing further dilatation of the annulus. recently, the three-dimensional geometry of the tricuspid valve has been shown and analyzed by means of data obtained from echocardiography, ct scan and magnetic resonance imaging. normal tricuspid annulus is characterized by a more prominent part in the anteroseptal commissure area near the aortic valve and right ventricular outflow tract and a deeper part in the posteroseptal commissure area near the coronary sinus ostium . based on these characteristics, new three-dimensional rings have been developed for tricuspid annuloplasty, such as the mc3 (edwards lifescience, irvine, ca) and the contour 3d (medtronic, minneapolis, mn). there are few studies concerning the short-term results of tricuspid rings implantation and almost none on the long-term, therefore this study aims to analyze the long-term results of tvr by implantation of the two new prosthetic ring models mentioned above. the aim of this study is the long-term analysis of the results of tricuspid annuloplasty with three-dimensional rings in patients with functional it.


Eligibility criteria:
inclusion criteria: * adult patients * operated for functional tr * implantation of three-dimensional tricuspid prosthetic ring mc3 or contour 3d, isolated or concomitant to surgery on the left heart sections * surgical access in median sternotomy or minithoracotomy exclusion criteria: - emergency/urgency intervention
therapeutic confirmatory clinical trial to evaluate the safety and efficacy of ag1321001 in chronic cougher

Conditions: Cough

Summary: this study is for therapeutic confirmation of ag1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.


Eligibility criteria:
inclusion criteria: 1. adult between the ages of 18 and 70. 2. patient who has cough symptom caused by following diseases: chronic bronchitis, bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis. 3. patient requiring internal treatment due to cough symptom, who has coughing more than 3 weeks. 4. patient who will continue to cough more than 1 week.(by physician's judgment) 5. patient who decided to participate in this clinical trial at his(her) own will and agreed in written letter of consent. 6. patient who is trustworthy, ready for cooperation and observing the restrictions during the trial period. exclusion criteria: 1. patient who is accompanied by the seriously abnormal symptom in respiratory system, such as acute infectious pulmonary disease, tuberculosis. 2. patient who has clinical history of sensitivity to xanthine drug. 3. patient who has peptic ulcer or asthma (except cicatrix) 4. patient whose liver or kidney function is seriously abnormal: including the cases of sgot, sgpt, bilirubin and blood creatinine value exceeding twice of their upper normal limit. 5. patient whose heart function is abnormal: including the case of showing abnormal ekg test value that is clinically significant. 6. patient who has experience to have participated in other clinical trial within two months before starting the trial. 7. pregnant woman, lactating woman. 8. patient who has convulsion or alcoholism. 9. patient who take medicines which can not use combination with ag1321001.

Keywords: cough chronic bronchitis pnds post nasal drip syndrome gerd gastroesophageal reflux disease bronchiectasis
pharmacokinetics, pharmacodynamics, safety and tolerability of oc-01 in adult chinese with dry eye disease

Conditions: Dry Eye Disease

Summary: the objective of this study is to evaluate the pharmacokinetics (pk) in adult chinese subjects with dry eye disease (ded)1 after bilateral nasal spray administration of oc-01 (varenicline solution) nasal spray at a concentration of 0.6 mg/ml.


Eligibility criteria:
inclusion criteria: have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to the screening visit exclusion criteria: * have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within 12 months of the screening visit * have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, acute conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with ded are allowed. * have a systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.) * have a known hypersensitivity to any of the procedural agents or investigational product components * have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.

Keywords: oc-01 (varenicline solution) dry eye disease
vitamin e supplements in preventing cancer in patients at risk of prostate cancer or who have prostate cancer

Conditions: Prostate Cancer

Summary: rationale: vitamin e supplements may stop or delay the development of prostate cancer in patients who are at risk of prostate cancer or who have prostate cancer. it is not yet known which vitamin e regimen is more effective in preventing prostate cancer. purpose: this randomized phase i trial is comparing vitamin e supplement regimens to see how well they work in preventing cancer in patients at risk of prostate cancer or who have prostate cancer.

objectives: * determine the effect of tocopherol supplementation on plasma and urine levels of α-, γ-, and δ-tocopherols, psa, and prostaglandin e_2 by comparing the blood and urine samples collected before and after the supplementation in patients with prostate cancer. * test the hypothesis that the supplementation reduced oxidative and nitrosative stress by measuring plasma levels of f_2-isoprostane, c-reactive protein, and 3-nitrotyrosine as well as urinary levels of 8-hydroxy-2-deoxyguanosine (8-ohdg). * determine the levels of α-, γ-, and δ-tocopherols in prostate tissues and analyze immunohistochemically (ihc) for cell proliferation, apoptosis, cyclooxygenase-2, 8-ohdg, and 3-nitropyrosine levels in prostate cancer/tissue slides. outline: patients are randomized into 1 of 3 arms. * arm i: patients receive no supplementation. * arm ii: patients receive oral high γ-tocopherol vitamin e supplementation once daily for 1 week. * arm iii: patients receive oral high γ-tocopherol vitamin e supplementation once daily for 2 weeks. blood, urine, and tissue samples are collected periodically and analyzed for oxidative/nitrosative stress and other markers (i.e., f2-isoprostane, 8-ohdg, 3-nitrotyrosine, prostaglandin e2, c-reactive protein, and psa), biomarkers in prostate tumors and nontumorous tissues (i.e., 8-ohdg, 3-nitrotyrosine, and cyclooxygenase-2) by ihc, and pharmacokinetics by high-performance liquid chromatography.

Eligibility criteria:
disease characteristics: * meets one of the following criteria: * abnormal digital rectal examination or abnormal prostate specific antigen (\> 4.0 ng/ml) * obstructing prostate * biopsy-proven prostate cancer * scheduled to undergo prostate surgery (i.e., transurethral prostatectomy or prostatectomy) patient characteristics: * no uncontrolled diabetes, uncontrolled blood pressure, chronic congestive heart failure, or history of renal insufficiency * no personal or family history of a bleeding disorder * no known history of problems absorbing dietary fats (e.g., crohn's disease, cystic fibrosis) prior concurrent therapy: * more than 2 weeks since prior nsaids or corticosteroids * no concurrent supplementation of vitamin e (a multivitamin containing ≤ 60 iu of vitamin e is allowed) * no concurrent colestipol or orlistat * no concurrent warfarin or dicumarol

Keywords: prostate cancer
surgical decompression for diabetic neuropathy in the foot

Conditions: Diabetic Polyneuropathy

Summary: the purpose of the study is to determine whether or not surgical decompression of the common peroneal, tibial, and deep peroneal nerves in the legs of persons with diabetic peripheral neuropathy is effective treatment.


Eligibility criteria:
inclusion criteria: * age \>18 years * presence of type 1 or 2 diabetes mellitus (fasting plasma glucose \> 7 mmol/l or casual plasma glucose \> 11.1 mmol/l and symptoms of diabetes or a 2hr plasma glucose in a 75g oral glucose tolerance test \> 11.1 mmol/l) * symptoms of paresthesias (including burning pain) or numbness present symmetrically in both feet, determined to be on a peripheral nerve basis * total neuropathy score of ≥ 2 based on symptoms, signs, and nerve conduction study abnormality * average pain on likert scale (range 0 - 10) ≥5 * good diabetic control with hgb a1c \< 8 * presence of tinel's sign at the tarsal tunnel * possession of valid ontario hospital insurance plan (ohip) coverage exclusion criteria: * other types of diabetes mellitus (gestational, drug-induced, etc.) * other cause of neuropathy than diabetes such as vasculitis, amyloidosis, toxic neuropathy, hiv, renal failure, alcohol abuse, etc. pure entrapment neuropathy without evidence of dsp * symptomatic lumbosacral spine disease * symptomatic lower extremity vascular disease * previous foot ulceration or amputation. other contraindications to surgery such as significant ankle edema, venous stasis, morbid obesity, or previous surgery/injury which would be incompatible with appropriate wound healing * history of peripheral arterial disease * hba1c \> 8.0 - adults lacking capacity to consent, pregnant women, prisoners, non-english speakers who require an interpreter, and those unwilling or unable to participate in the full study follow-up

Keywords: diabetic sensorimotor polyneuropathy
evaluation of the long term follow up of the efficacy of oc-01 nasal spray on signs and symptoms of dry eye disease

Conditions: Long Term Follow up Dry Eye Disease

Summary: the objective of this safety long-term follow-up study was to evaluate the safety of oc-01 nasal spray at 6 months and 12 months post treatment in the opp-002 study (nct03636061).

study opp-002-01 was a long-term follow-up study of those subjects who had previously participated in the opp-002 study (nct03636061). the opp-002 study is a phase 2, multicenter, randomized, double-masked, placebo-controlled study designed to evaluate the safety and efficacy of oc-01 nasal spray in adult participants with dry eye disease. the first scheduled visit occurs 6 months after the first treatment of oc-01 nasal spray/placebo in the opp-002 study. the second scheduled visit occurs 12 months after the first treatment of oc-01 nasal spray/placebo in the opp-002 study.

Eligibility criteria:
inclusion criteria: 1. have been enrolled in the opp-002 study 2. have received at least one dose of the study drug/placebo in opp-002 study 3. completed the opp-002 study to visit 5 4. have provided verbal and written informed consent exclusion criteria: 1. have discontinued prior to visit 5 in the opp-002 study.
personalised program for women treated for hodgkin disease

Conditions: Hodgkin Disease; Breast Cancer

Summary: after treatment for hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death. the investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and rmi.


Eligibility criteria:
inclusion criteria: * women \> 18 years * treated for hodgkin disease * signed informed consent * high risk of breast cancer exclusion criteria: * patients unable to have a regular follow-up

Keywords: hodgkin disease breast cancer